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College of Rheumatology criteria for 20% improvement (ACR20 criteria). Data was
obtained from a comprehensive literature review using PubMed, Medline, and
Cochrane library. Efﬁ cacy values were obtained from published randomized clinical 
trials. A decision tree analyses was conducted followed by one-way and two-way 
sensitivity analyses. Costs and efﬁ cacy values associated with therapeutic options were 
varied in the sensitivity analyses. RESULTS: The probability of achieving ACR20
response for ETANMTX, ADALMTX, INFLMTX, and MTX were 85.5%, 
65.95%, 61.26%, and 39.94%, respectively. The probability of an adverse drug event 
occurrence for ETANMTX, ADALMTX, INFLMTX, and MTX were 14.0%, 
6.5%, 7.9%, and 9.5%, respectively. The analysis revealed that ETANMTX option 
was the most cost-efﬁ cacious, with an annual cost of $52,369 to the patient. The
annual cost savings with ETANMTX combination use would be $19,318. Annual
costs of ADALMTX, INFLMTX, and MTX monotherapy were $79,058, $68,932, 
and $67,071 respectively. Results were robust to both one-way and two-way analysis. 
CONCLUSIONS: Etanercept plus Methotrexate combination therapy was a better 
option based on the ACR 20 outcome measure considered. An analysis using real
world data and/or a prospective head-to-head comparison study could provide better 
conclusive evidence for decision-makers.
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OBJECTIVES: An observational study comparing risedronate to alendronate (REAL) 
in a subgroup of postmenopausal osteoporotic (PMO) women with prior fracture
demonstrated that treatment with risedronate reduced the incidence of hip fracture by
66% in the ﬁ rst year of treatment (Delmas, 2008). The objective of this analysis was 
to determine the cost-effectiveness of risedronate compared to alendronate at generic
pricing using these effectiveness data in a high risk PMO population in the U.S. 
METHODS: A validated Markov model of osteoporosis (Tosteson, 2001) was used 
to estimate the impact of therapy on hip fractures, costs, and quality-adjusted life
years (QALYs). The model simulated a cohort of 1000 women ages 65 with 
BMDa2.5 and a previous vertebral fracture, treated with risedronate or alendronate
for one year. Associated costs and QALYs were tracked for an additional two years 
in each arm. Hip fracture incidence and mortality rates, as well as drug (generic alen-
dronate 93.5% lower than risedronate) and hip fracture costs were extracted from
published literature. RESULTS: In a cohort of 1000 women treated with risedronate 
versus alendronate, the model predicted 25 fewer hip fractures and 8.41 additional 
QALYs, resulting in a cost savings of $330,378. Extrapolating to a population of PMO 
women with a prior vertebral fracture in the U.S. suggests that risedronate prevents
over 114,000 fractures in roughly 4.6 million women at cost savings of over $1,515 
million. A sensitivity analysis assuming treatment for 2 years and parity efﬁ cacy in
year 2 resulted in a cost per QALY gained for earlier fracture protection of $9925
(cost per fracture averted: $3419) when treating with risedronate versus alendronate
in the population 65. Risedronate remains cost-saving in the 80 population. CON-
CLUSIONS: Based on “real world” data this analysis suggests risedronate’s early
fracture protection results in favorable cost-effectiveness versus generic alendronate
despite its higher drug cost.
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OBJECTIVES: To determine and quantify the key drivers of cost-effectiveness in 
osteoarthritis (OA) treatment with traditional NSAIDs and COX-2 selective pharma-
ceuticals. METHODS: Cost effectiveness analysis (CEA) in OA treatment with tradi-
tional NSAIDs and COX-2 selective pharmaceuticals focus on side effects given the 
non-signiﬁ cant differences in efﬁ cacy (pain relief) among treatments. The most fre-
quently included side-effects and complications in OA CEA analysis are gastrointesti-
nal (GI) complications and myocardial infarction (MI). Given the concern about
broader cardiovascular (CV) risks associated with NSAID treatment, the scope of a
recently published Markov model (ﬁ ve-year horizon, three-month cycles, health care
perspective) was expanded to include four additional CV events (stroke, coronary
insufﬁ ciency, venous thromboembolism and angina). Two treatments priced at 1) the 
average of celecoxib and etoricoxib, and 2) ibuprofen were evaluated. The model was 
populated with UK data. Absolute and relative GI risks were derived from a recent 
NICE HTA report whereas absolute CV risks were assumed to equal the normal 
population risk and relative CV risks were taken from the literature. The model was 
used to determine the most important drivers of cost-effectiveness in OA treatment. 
This was done by evaluating the responsiveness of the ICER to a 1% change in the 
input variable of interest, controlling for changes in all other variables. RESULTS:
The ﬁ ve most inﬂ uential variables were (% impact on ICER resulting from 1% change
in the variable): Quality of life in arthritis (2.5%), relative risk of CV events (1.5%), 
relative risk of mild GI events (1.3%), price of the COX-2 pharmaceutical (1.3%) and 
quality of life in dyspepsia (0.7%). CONCLUSIONS: Whilst the most important cost-
effectiveness driver in OA treatment is overall quality of life changes, the analysis
indicate that there might be higher economic beneﬁ ts associated with decreasing CV 
risks rather than decreasing aspects of GI risk.
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OBJECTIVES: Injection site reactions (ISR) are the most common type of adverse 
event associated with the subcutaneous use of the tumor necrosis factor inhibitor 
(Anti-TNF) agents, etanercept (Enbrel) and adalimumab (Humira). The purpose of 
this study was to 1) investigate the incidence and characteristics of ISR, and 2) capture
the humanistic and economic consequences of ISR in patients who received etanercept
and/or adalimumab for rheumatoid arthritis (RA). METHODS: RA patients were 
identiﬁ ed through a query of outpatient claims with an ICD-9 code for RA and prac-
tice code for Jefferson Rheumatology Associates, Philadelphia, PA. Patients who met 
inclusion criteria of q18 years old and having received etanercept or adalimumab in
the past 3 years were administered a one-time observational survey developed by the 
investigators. RESULTS: The study included thirty patients, ﬁ ve of which had used
both adalimumab and etanercept. The overall prevalence of ISR was 56.3% (9
patients, n  16) for adalimumab and 84.2% (16 patients, n  19) for etanercept. 
Clinical characteristics of ISR included erythema (44.4%–68.8%), pruritus (44.4%–
68.8%), and swelling (33.3%–56.3%). Only one patient (3.3%) in the cohort was 
pre-medicated for ISR. Three patients in the adalimumab (n  9, 33.3%) and one 
patient in the etanercept group (n  16, 6.25%) called their physician when experienc-
ing a ﬁ rst-time ISR. Ice was the most common form of treatment for the ﬁ rst, typical, 
and worst incidence of ISR. No patients reported going to the ER, taking antihista-
mines, or using analgesics to treat ISR. Two patients (22.2%) and no patients discon-
tinued therapy due to ISR in the adalimumab and etanercept group, respectively. No
missed work-days were reported in either group due to ISR. CONCLUSIONS: ISR 
occurred in over half of the patient cases studied, and was largely characterized by 
erythema, pruritis, and swelling. Patient counseling about ISR is essential since self-
treatment is common and discontinuation may result.
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OBJECTIVES: Psoriatic arthritis (PsA) is an inﬂ ammatory arthritis occurring in about 
10–30% of the patients with psoriasis. Registration of highly effective but costly bio-
logical drugs for the treatment of PsA gave an extra impulse to economic evaluations
in rheumatology. There are no data on cost-of-illness of PsA neither from Hungary 
nor from countries with similar economic status (i.e. Poland, Slovakia and Czech 
Republic). The main goal of present study was to collect data on disease burden and 
costs of patients with PsA in Hungary. METHODS: A cross sectional questionnaire
survey of consecutive patients aged q18 years with diagnosis of PsA was conducted 
in 8 hospital based rheumatology outpatient centres in Hungary in 2008. Data were 
collected by rheumatologists during routine outpatient visits. Observed variables were 
demographic data, disease duration, disease activity score (DAS28), psoriasis area
severity index (PASI), drug use, the use of aids and devices, imaging, gastroscopy, 
outpatient visit, admissions to hospital, orthopaedic surgery, spa, physiotherapy, home 
care, transportation, non-reimbursed health care services, home remodelling and infor-
mal care. Data on PsA related reduction of working hours, sick leave and disability 
pension were collected also. RESULTS: A total of 183 patients were enrolled, of these, 
104 (57%) were women. The mean age of the sample was 50.3 (SD 12.9) years and 
the mean disease duration was 9.2 (9.2) years. The annual average direct, indirect and 
total costs were 2 670, 2 904 and 5 574 euros/patient/year in PsA, respectively. The 
main cost domains were the productivity losses due to work disability (49%) and the 
costs of biologic therapies (18%), with 2 742 (SD 4 920) and 1 008 (SD 4 134) 
euros/patient/year, respectively. CONCLUSIONS: Our study showed that the eco-
nomic burden of PsA is considerable in Hungary and provided a baseline to evaluate 
the economic effect of treatments in PsA.
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OBJECTIVES: Assess direct (medical and drug) and indirect (workloss) costs of 
osteoporotic patients with non-vertebral (NV) fractures. METHODS: Osteoporosis 
patients (ICD-9-CM code 733.0) were identiﬁ ed (1999–2006) from an employer
claims database (^8,000,000 privately-insured beneﬁ ciaries; ages 18–64) and the
Medicare Standard Analytic Files 5% sample (ages 65). Osteoporotic patients with 
NV fracture (femur, pelvis, lower leg, upper arm, forearm, rib, or hip) were randomly 
matched on age, gender, employment status, and geography to osteoporotic controls. 
